1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Vaxcell-Bio Therapeutics Co., Ltd.

Vaxcell-Bio Therapeutics Co., Ltd.

323990.KQ
Vaxcell-Bio Therapeutics Co., Ltd.KR flagKOSDAQ
4,420.00
KRW
-120.00
- -
102.43BMarket Cap

Total Valuation

Vaxcell-Bio Therapeutics Co., Ltd. carries a market capitalization of 102.43B, placing it among publicly traded companies globally. Its enterprise value stands at 158.38B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap102.43B
Enterprise Value158.38B

Share Statistics

Vaxcell-Bio Therapeutics Co., Ltd. currently has 23.17M shares outstanding.

Shares Outstanding23.17M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 25.66, and the price-to-book ratio stands at -2.93.

PE RatioN/A
PS Ratio25.66
PB Ratio-2.93
P/TBV Ratio3.51
P/FCF Ratio-66.67
P/OCF Ratio-17.10

Enterprise Valuation

EV / Sales23.05
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

Vaxcell-Bio Therapeutics Co., Ltd. maintains a current ratio of 6.15, meaning it holds 6.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.13, indicating elevated leverage, while an interest coverage ratio of -71.90 demonstrates limited ability to service its debt obligations.

Current Ratio6.15
Quick Ratio4.83
Debt / Equity3.13
Debt / EBITDA-0.11
Interest Coverage-71.90

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-20.01
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover24.43

Stock Price Statistics

Vaxcell-Bio Therapeutics Co., Ltd.'s stock has declined approximately -54.24431% over the past 52 weeks. The 50-day moving average sits at 5,877.40, while the 200-day moving average is 8,442.55.

Beta (5Y)N/A
52-Week Price Change-54.24431%
50-Day Moving Average5,877.40
200-Day Moving Average8,442.55
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Vaxcell-Bio Therapeutics Co., Ltd. generated 6.87B in revenue and converted that into -14.69B in net income, yielding earnings per share of -635.81. EBITDA reached -15.81B, while operating income came in at -15.81B.

Revenue6.87B
Gross Profit801.52M
Operating Income-15.81B
Pretax Income-14.69B
Net Income-14.69B
EBITDA-15.81B
EBIT-15.81B
Earnings Per Share (EPS)-635.81

Balance Sheet

Vaxcell-Bio Therapeutics Co., Ltd. holds 19.74B in cash and equivalents against 1.79B in total debt, resulting in a net debt position of -10.37B. Total book value stands at -60.17B, with working capital of 21.04B providing operational flexibility.

Cash & Cash Equivalents19.74B
Total Debt1.79B
Net Debt-10.37B
Equity (Book Value)-60.17B
Book Value Per Share-2,603.53
Working Capital21.04B

Cash Flow

Vaxcell-Bio Therapeutics Co., Ltd. produced -10.31B in operating cash flow over the past twelve months. After subtracting -7.67B in capital expenditures, free cash flow totaled -17.98B - equivalent to -777.83 per share.

Operating Cash Flow-10.31B
Capital Expenditures-7.67B
Free Cash Flow-17.98B
FCF Per Share-777.83

Margins

Vaxcell-Bio Therapeutics Co., Ltd. operates with a gross margin of 11.66, reflecting its pricing power and cost economics. The operating margin of -230.03 and net profit margin of -213.81 provide insight into operational efficiency.

Gross Margin11.66
Operating Margin-230.03
Pretax Margin-213.81
Profit Margin-213.81
EBITDA Margin-230.03

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield0.78
FCF Yield-1.50

Stock Splits

Vaxcell-Bio Therapeutics Co., Ltd.'s most recent stock split took place on November 10, 2023 with a 5:6 split ratio.

Last Split Date11/10/2023
Split Ratio5:6

Scores

Vaxcell-Bio Therapeutics Co., Ltd. posts an Altman Z-Score of 14.45, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score14.45